ArticleFrontiers in medicine2026
Hydroxyurea treatment for sickle cell disease in Nairobi informal settlements: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sickle Cell Disease (SCD) causes acute and chronic complications. Hydroxyurea (HU) reduces vaso-occlusive crises (VOCs) and improves patients' outcomes. However, evidence on the real-world implementation and effectiveness of HU in resource-limited primary care settings, particularly those serving informal settlements, remains scarce. This study evaluates HU use and its effects in two Nairobi clinics serving informal settlements. Methods: We retrospectively analyzed 2,206 clinical visits from 328 SCD (HbSS) patients (March 2019-March 2021), comparing complication rates in HU users and non-users. Linear mixed and competing-risk Cox regression models assessed HU's effects on laboratory markers and clinical outcomes. Results: HU users had lower incidence rates of VOCs (19.6 vs. 24.7 per 10 person-years) and infections (11.3 vs. 12.4) than non-users. Adjusted analyses showed HU increased hemoglobin (+0.36 g/dL, 95% CI: 0.19 to 0.53) and MCV (+3.47 fl, CI: 2.20 to 4.73). HU reduced the hazard of VOC (HR = 0.82, 95% CI: 0.66 to 1.02) and infections (0.72, 0.55 to 0.95), but evidence for an effect on major complications was inconclusive due to substantial imprecision (1.39, 0.40 to 4.78). Lower HU doses (<20 mg/kg/day) had similar hazard of VOCs as higher doses (20-25 mg/kg/day), but reduced infection and major complication risks. Conclusion: HU reduces infections and VOCs, but does not relevantly impact major complications. Long-term studies are needed to evaluate its effectiveness in low-resource settings, where adherence is influenced by accessibility and socio-economic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.